Skip to main content

Table 4 Summary of TEAEs and TESAEs in the four groups

From: Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

  Arm A Arm B Arm C Arm D
(N=59) (N=62) (N=58) (N=59)
  N(%) N(%) N(%) N(%)
TEAEs:     
Subject with at least one TEAE 57 (96.6) 58 (93.5) 53 (91.4) 56 (94.9)
Subject discontinued the study due to TEAE 4 (6.8) 4 (6.5) 6 (10.3) 8 (13.6)
Subjects with at least one chemotherapy-related TEAE 56 (94.9) 57 (91.9) 50 (86.2) 55 (93.2)
Subjects without TEAE 2 (3.4) 4 (6.5) 5 (8.6) 3 (5.1)
TESAEs:     
Subject with at least one TESAE 9 (15.3) 10 (16.0) 7 (12.1) 11 (18.6)
Subjects with at least one chemotherapy-related TESAE 5 (8.5) 4 (6.5) 3 (5.2) 5 (8.5)
  1. Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.
  2. TEAE: Treatment-emergent Adverse Events, TESAE: Treatment-emergent Serious Adverse Events.